NTRR Aiming to Acquire Medical Marijuana Facility, Starts Talks on Colorado Sites

LAS VEGAS, NV / ACCESSWIRE / June 2, 2016 / Neutra Corp. (OTCQB: NTRR) is opening discussions on acquiring a 100 percent interest in a medical marijuana dispensary and/or cultivation center in Colorado and has narrowed its focus to several promising and available locations in the Centennial State. The company is also looking over similar facilities in California.

“Medical marijuana has gained great public acceptance since legalization and offers tremendous opportunities for growth,” said NTRR CEO Chris Brown. “Expansion into dispensing and/or cultivating can help NTRR further tap into the market’s near-limitless revenue potential as more and more medicinal uses are found for this versatile and beneficial product. We’ve identified several promising dispensary/cultivation sites in Colorado ready for quick acquisition and California holds great interest for us as well.”

Published figures indicate the U.S. regulated cannabis market (including medical and recreational use) will easily top $7.1 billion in 2016 and is projected to swell to more than $23 billion by 2020. Legal sales of the substance tripled in 2015 alone.

NTRR is hard at work marketing and promoting new, antimicrobial alternatives to harsh chemicals used in cannabis farms. In 2016, NTRR plans to continue to source out solutions for cannabis producers and consumers alike as the regulated cannabis industry continues to swell in the United States, Canada and beyond. For more information on the company’s mission, please visit http://neutrainc.com/investors.

About
Neutra Corp.

As the global cannabis market grows exponentially, it is constantly in need of better technologies and products to be more efficient in how they grow, what they grow, and how they consume cannabis and its related products. From lighting to dosage devices, from pesticide replacements to plant enhancers, NTRR is constantly combing the industry for the latest and greatest to test, prove and bring to market.

By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (NASDAQ: GWPH), Cara Therapeutics Inc. (NASDAQ: CARA) and 22nd Century Group, Inc. (NASDAQ: XXII). For investing information and performance data, please visit www.neutrainc.com.

Notice
Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact:

Neutra Corp.
Chris Brown, 813-367-2041
President and CEO
info@neutracorp.com

SOURCE: Neutra Corp.

ReleaseID: 440643